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ABSTRACT
Objective: To use patient-level data from the
ADVANCE study to evaluate the cost-effectiveness of
transcatheter aortic valve implantation (TAVI) compared
to medical management (MM) in patients with severe
aortic stenosis from the perspective of the UK NHS.
Methods: A published decision-analytic model was
adapted to include information on TAVI from the
ADVANCE study. Patient-level data informed the choice
as well as the form of mathematical functions that were
used to model all-cause mortality, health-related quality
of life and hospitalisations. TAVI-related resource use
protocols were based on the ADVANCE study. MM was
modelled on publicly available information from the
PARTNER-B study. The outcome measures were
incremental cost-effectiveness ratios (ICERs) estimated
at a range of time horizons with benefits expressed as
quality-adjusted life-years (QALY). Extensive sensitivity/
subgroup analyses were undertaken to explore the
impact of uncertainty in key clinical areas.
Results: Using a 5-year time horizon, the ICER for the
comparison of all ADVANCE to all PARTNER-B patients
was £13 943 per QALY gained. For the subset of
ADVANCE patients classified as high risk (Logistic
EuroSCORE >20%) the ICER was £17 718 per QALY
gained). The ICER was below £30 000 per QALY
gained in all sensitivity analyses relating to choice of
MM data source and alternative modelling approaches
for key parameters. When the time horizon was
extended to 10 years, all ICERs generated in all
analyses were below £20 000 per QALY gained.
Conclusion: TAVI is highly likely to be a cost-effective
treatment for patients with severe aortic stenosis.
INTRODUCTION
Transcatheter aortic valve implantation
(TAVI) has become the standard of care for
patients with severe symptomatic aortic
stenosis (AS) who are considered at extreme
or prohibitive risk for surgical aortic valve
replacement and as an acceptable alternative
to surgery for those at high risk.1 However,
these treatments are expensive, with high
index costs due to the expense of the pros-
thesis. Typical TAVI candidates are costly to
care for without intervention due to repeated
hospitalisation and heart failure (HF) therap-
ies.2 Furthermore, their quality and quantity
of life is poor without treatment.3 4
The UK National Institute of Health and
Care Excellence (NICE)5 is charged with
KEY MESSAGES
What is already known about this subject?
▸ Severe symptomatic aortic stenosis in patients
who cannot receive surgical aortic valve replace-
ment carries a poor prognosis. The introduction
of transcatheter aortic valve implantation has
offered an opportunity for improved outcomes
in this patient group.
What does this study add?
▸ This study is a cost-effectiveness analysis of
TAVI using evidence from the 'real world'
ADVANCE study and the CoreValve system. This
is the first formal cost-effectiveness analysis
using data for the CoreValve system and con-
cludes that TAVI is likely to represent a cost-
effective intervention as compared to medical
management.
How might this impact on clinical practice?
▸ In properly selected patients, TAVI offers sub-
stantial improvements in symptoms and life
expectancy and is likely to represent a cost-
effective use of healthcare budgets.
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considering the clinical and cost-effectiveness of treatments
and then with making recommendations as to their provi-
sion within the National Health Service (NHS). Cost-utility
analysis assesses two or more alternative courses of action in
terms of their costs and beneﬁts. The comparison is sum-
marised using the expected incremental cost-effectiveness
ratio (ICER). This is a measure of the additional cost per
additional unit of health gain produced by one intervention
compared to another. NICE’s preferred form of cost-
effectiveness analysis uses the quality-adjusted life-year
(QALY) to describe the outcome of each intervention. By
extension, NICE’s preferred form of ICER is the cost per
QALY gained.
We aimed to measure the cost-effectiveness of TAVI
implantation by comparing costs and beneﬁts of patients
receiving TAVI as part of the ADVANCE study, with those
receiving medical management (MM) in Cohort B of
the PARTNER (Placement of Aortic Transcatheter
Valves) study (henceforth referred to as PARTNER-B).
METHODS
Data sources
Individual patient data (IPD) from the international
Medtronic CoreValve ADVANCE study were used to
model costs and beneﬁts of the TAVI cohort.6 One of
the largest and most rigorous TAVI postmarket studies to
date, ADVANCE comprises over 1000 patients from 44
centres in 12 countries in Western Europe, Asia and
South America. From March 2010 to July 2011, 1015
patients were enrolled in the ADVANCE study, of which
996 patients underwent attempted implant with the
CoreValve device. The mean age was 81.1±6.4 years
(range 51–96 years) and 51% were female. The baseline
peak and mean aortic valve gradients were 75.9±25.1
and 45.6±15.5 mm Hg, respectively, and the mean aortic
valve area was 0.7±0.3 cm2. The median (Q1, Q3) logistic
EuroSCORE was 16% (10.3, 25.3%) and the median
(Q1, Q3) STS score was 5.3% (3.6, 7.8%). Twelve
months of follow-up data were used as the basis of all
analyses. Patient source data were 100% monitored and
events were independently adjudicated. Over 120
patients from the ADVANCE study were recruited from
ﬁve UK centres; the baseline characteristics of these
patients were not signiﬁcantly different from the cohort
overall. Data from the PARTNER-B randomised trial
were used to parameterise the MM arm of the
model.3 7 8
Model description
We used the analytical framework of a previously pub-
lished model to inform this analysis.9 Brieﬂy, two separ-
ate Markov models were used to characterise what
happens to a TAVI patient in the ﬁrst 30 days postproce-
dure and for the remainder of their lifetime, respect-
ively. Cycle lengths of 1 day and 1 month were applied in
the short-term and long-term models, respectively.
Contingent on being alive at the end of the short-term
model, all individuals enter the long-term model where
they remain until dead. An individual can be in the fol-
lowing health states: dead, alive at home, or alive in hos-
pital for an additional TAVI-related procedure. Heart
failure-related rehospitalisations are included as a cost
rather than a health state and can be experienced by all
patients who are alive regardless of health state. TAVI
patients enter the model in the surgical procedure
health state and MM patients in the alive at home
health state. Parametric survival functions were ﬁtted to
the relevant mortality data and extrapolated for the time
horizon speciﬁed in the model.
The model schematic is presented in ﬁgure 1. Each
health state is associated with costs and utilities that
patients accrue throughout the model. The accrual
process is continued for a ﬁxed time period (the cycle
length) and results are expressed as lifetime costs (£UK)
and beneﬁts (QALYs). Patients were entered into the
short-term model with a median starting age of 82 years,
based on the mean age from the ADVANCE study. The
model was constructed in Microsoft Excel and was run
Figure 1 Model schematic
(TAVI, transcatheter aortic valve
implantation).
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for a time horizon of 5 years. A UK NHS perspective was
used with discount rates of 3.5% per annum for costs as
well as utilities.5
To explore the implications of patient-level heterogen-
eity on cost-effectiveness, in addition to using all patients
we stratiﬁed patients in the ADVANCE study into high-
risk and low-risk groups deﬁned using the reported
Logistic EuroSCORE, used to calculate the predicted
operative mortality for patients undergoing cardiac
surgery (High/Low: split score=20%).
Estimating mortality
A range of parametric survival functions were ﬁtted to
the time-to-event data which included: exponential,
Weibull, Gompertz, log-normal, log-logistic and Gamma
functions.10 The choice of distribution for the cost-utility
model was based on within trial ﬁt and clinically plaus-
ible extrapolation beyond the trial data. The former was
assessed by comparing Akaike Information Criteria
(AIC) and Bayesian Information Criteria (BIC), and
also by examining Cox-Snell residual plots. The latter
was assessed by visual assessment of the extrapolated sur-
vival beyond the trial period. The proportional hazards
assumption was assessed through a log-cumulative
hazard plot of the survival data and examining
Schoenfeld residuals by risk group.10
Estimating health-related quality of life
Health-related quality of life (HRQoL) was included into
the model as utilities using ADVANCE EQ-5D (EuroQol)
values for TAVI, with reported patient-level EQ-5D scores
mapped to utility weights using standard UK tariffs.11
A random intercepts multilevel model was constructed
to estimate HRQoL over time using the utility weights.
The model accounts for baseline utility deviating from
the mean. A random effects intercept and gradient
model was also investigated, which allows for differences
in the trajectory of utility over time between patients in
addition to differences at baseline. The chosen model
was restricted to never exceed the age-adjusted and
gender-adjusted EQ-5D population norms.
For patients receiving MM, a ﬁxed utility decrement
based on the PARTNER-B data was applied to the
age-adjusted and gender-adjusted population norms as
described in Watt et al.9
Estimating hospitalisations
In the base case, all-cause rehospitalisation rates were
captured using a time-dependent function, allowing the
rates to vary over time. The time-dependent rates were
based on PARTNER-B data,8 where Weibull distributions
for TAVI and MM were ﬁtted independently to model
the time to ﬁrst rehospitalisation. This approach
assumes that the differences in device choice and
patient characteristics do not have an impact on hospi-
talisation rates. Considering the potential heterogeneity
we have identiﬁed between the cohorts, we performed a
sensitivity analysis on this assumption by using a ﬁxed
rate of hospitalisation derived from either ADVANCE or
the literature12 in every model cycle.
Resource use and unit costs
Treatment costs were sourced from the latest British
National Formulary.13 Additional costs were sourced,
where available, from publicly accessible databases14 15
or from a recent UK-based analysis of TAVI carried out
on behalf of NICE.16 Resource use data including time
spent in different hospital departments and overall
length of stay were taken from ADVANCE. In order to
fully align the underlying MM hospitalisation rate and
costs we have included the PARTNER-B balloon aortic
valvuloplasty (BAV) rate into the model.3 Hourly proced-
ure costs were taken from Raikou et al17 and inﬂated to
current values using an appropriate inﬂation index.15
Key parameter inputs are presented in online supple-
mentary tables S1/S2.
Sensitivity analyses
Detailed analyses relating to three elements of uncer-
tainty were undertaken. First, for each of the two main
comparisons a full exploration of parameter uncertainty
was undertaken via probabilistic sensitivity analyses.
Second, a deterministic assessment of parameter uncer-
tainty was undertaken for the key clinical comparison
(ADVANCE high risk vs all PARTNER-B MM) patients.
Finally, due to the number of different approaches that
could be used to model key aspects of the patient
pathway (structural uncertainty), a series of scenario
analyses were performed to explore the implications of
alternative choices.
In addition to the analyses described above, we also
assessed the sensitivity around the survival data for MM
patients by exploring the use of different mortality
sources from PARTNER-B: 1-year data,3 2-year data,8
3-year data,7 with and without BAV8 and the Society of
Thoracic Surgery (STS) Score <5% subgroup.8 In add-
ition, we used external data sources as an alternative to
PARTNER-B to model mortality for MM patients.18 19
We also explored alternative assumptions relating to
location of death and differences in degenerative valve
disease in all HF hospitalisation events. Finally, we
explored the implications of alternative choices of time
horizon on cost-effectiveness.
CLINICAL RESULTS
Patient characteristics
Baseline characteristics in all key patient groups are pre-
sented in table 1. Highly signiﬁcant differences
(p<0.001) were identiﬁed in all patients recruited into
ADVANCE and the PARTNER-B MM arm for a number
of key cardiovascular endpoints including atrial ﬁbrilla-
tion, coronary artery disease, cerebrovascular disease,
Logistic EuroSCORE and the proportion of patients
with New York Heart Association (NYHA) class III or IV
HF. Restricting the comparison to those in the
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ADVANCE high-risk group, fewer signiﬁcant differences
were observed and there were no longer any signiﬁcant
differences in logistic EuroSCORE, prior myocardial
infarction (MI) and prior pacemaker usage. While not
an element of this analysis, the differences between the
TAVI arm of the PARTNER-B study and the ADVANCE
high-risk group were even less pronounced. Differences
in Logistic EuroSCORE (%), coronary artery disease
(%) and atrial ﬁbrillation (%) were 26.4 vs 32.3, 67.6 vs
66.1 and 32.9 vs 36.3 for the TAVI arm of the
PARTNER-B study and the ADVANCE high-risk group,
respectively.6 7
Predicted survival
There was strong evidence to suggest the proportional
hazards assumption was violated for treatment-speciﬁc
all risk groups, and hence independent survival curves
were used. The Weibull function was chosen to model
survival for all patient groups (see online supplementary
table S3).
Alongside the function for all patients, these survival
functions were restricted to not exceed the age-speciﬁc
and gender-speciﬁc population survival sourced from
UK life tables.20 A comparison of the raw and ﬁtted data
is presented in ﬁgure 2A. Based on the ADVANCE high-
risk cohort, 1-year survival for TAVI patients was 77%
and 5-year survival 44%. For all ADVANCE patients the
predicted 1-year and 5-year survival estimates were 83%
and 56%, respectively. In comparison, MM patients had
a 53% chance of survival at 1 year and a 5% chance of
surviving to 5 years, using the 3 years PARTNER-B data
(ﬁgure 2B).
When expressed using a numbers needed to treat
(NNT) metric the value generated using the 5-year time
Figure 2 (A) Within trial goodness of fit for main patient groups. (B) Long-term extrapolation for all main patient groups (TAVI,
transcatheter aortic valve implantation).
Table 1 Baseline characteristics for ADVANCE and PARTNER-B medical management
ADVANCE PARTNER-B
p Values (ADVANCE vs
PARTNER-B)
All
patients
High-risk cohort
(EuroSCORE>20%)
Medical
management
All
patients
High-risk
cohort
N 1015 369 179
Mean age in years (±SD) 81.1±6.4 82.7±5.7 83.0±8.0 0.001 0.614
Male (%) 49.4 49.9 46.9 0.537 0.510
Logistic EuroSCORE, % (±SD) 19.4±12.3 32.3±11.0 30.4±19.1 <0.001 0.141
NYHA III/IV (%) 79.6 84.6 93.9 <0.001 0.002
Diabetes (%) 31.3 27.1 Not reported NA NA
Coronary artery disease (%) 57.6 66.1 74.3 <0.001 0.052
Peripheral vascular disease (%) 19.5 27.1 25.1 0.086 0.617
Atrial fibrillation (%) 32.9 36.8 48.8 <0.001 0.005
Cerebrovascular disease (%) 12.9 17.6 27.5 <0.001 0.007
Prior MI (%) 16.0 22.0 26.4 0.001 0.289
Prior PCI (%) 31.1 36.0 24.8 0.090 0.009
Prior CABG (%) 21.4 34.7 45.6 <0.001 0.014
Prior permanent pacemaker (%) 12.9 16.5 19.5 0.017 0.384
CABG, coronary artery bypass graft; MI, myocardial infarction; NYHA, New York Heart Association; PCI, percutaneous coronary intervention.
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horizon for all ADVANCE patients compared to all
PARTNER-B MM is 2.0. The corresponding value for the
comparison of the ADVANCE high-risk group to all
PARTNER-B MM patients is 2.6.
Other clinical endpoints
A random effects intercept model was chosen to esti-
mate utility over time for TAVI patients based on the
ADVANCE data (see online supplementary table S5).
The model predicted a monthly utility increase of 0.002
(95% CI −0.002 to 0.006).
Using the time-dependent hospitalisation function,
estimated from the PARTNER-B data, the predicted
probability of HF-hospitalisation in the ﬁrst year is lower
for TAVI patients (18.4%) compared to MM patients
(44.5%), using the ADVANCE high-risk group for all
patients receiving TAVI and all PARTNER-B patients for
the MM mortality data. Using the ADVANCE data a
ﬁxed rate of 0.668 events per month was estimated and
was applied as a sensitivity analysis in the TAVI arm.
Cost-utility results
The probabilistic cost-effectiveness results are presented
in table 2 and the cost-effectiveness plane for both com-
parisons is presented in ﬁgure 3. The ICER for the most
optimistic comparison (all ADVANCE vs all
PARTNER-B) and also the most clinically plausible com-
parison (ADVANCE high risk vs all PARTNER-B) are
below the threshold values used by NICE in their
decision-making process (£20 000 per QALY gained)
and in both cases, TAVI was more likely than not to be
cost-effective (minimum probability=83.4%). The corre-
sponding values generated using a longer time horizon
(10 years) are presented in the online supplementary
table S6 with all ICERs being lower than £13 000 per
QALY gained.
The results generated using the ADVANCE high-risk
data for TAVI, but parameterised solely using a range of
data from the PARTNER-B study as well as two other his-
torical AS publications are reported in table 3 (time
horizon=5 years) and online supplementary table S7
(time horizon=10 years). In only 3 of 16 analyses was the
ICER above £20 000 per QALY gained (max value:
£27 790). With the exception of the clinically implausible
comparison of ADVANCE high-risk and PARTNER-B
low-risk patients, all ICERs generated using PARTNER-B
survival data are below £20 000 per QALY gained.
Sensitivity analyses
The parameters in the model that had the greatest
impact on the ICER are presented in ﬁgure 4.
The model was most sensitive to changes in the cost of
an MM HF hospitalisation event. Changing the
acquisition cost of TAVI by ±15%, or assuming that every-
one in the TAVI arm required additional pacing, did not
generate an ICER in excess of £20 000 per QALY
gained.
Ta
b
le
2
P
ro
ba
bi
lis
tic
ec
on
om
ic
re
su
lts
ge
ne
ra
te
d
us
in
g
a
5-
ye
ar
tim
e
ho
riz
on
M
M
TA
V
I
In
cr
em
en
ta
lv
al
u
es
P
ro
b
ab
ili
ty
th
at
TA
V
Ii
s
co
st
-e
ff
ec
tiv
e
at
£2
0
00
0/
Q
A
LY
th
re
sh
o
ld
(%
)
P
ar
am
et
er
C
o
st
s
B
en
ef
its
C
o
st
s
B
en
ef
its
C
o
st
s
B
en
ef
its
IC
E
R
*
P
re
vi
ou
sl
y
pu
bl
is
he
d
m
od
el
†
£5
00
0
0.
80
£3
0
20
0
2.
36
£2
5
20
0
1.
56
£1
6
20
0
10
0
A
D
V
A
N
C
E
hi
gh
ris
k
vs
al
lP
A
R
T
N
E
R
-B
£1
3
12
0
(£
11
21
6,
£1
5
33
9)
0.
78
(0
.7
3,
0.
82
)
£3
5
12
9
(£
30
79
0,
£3
9
96
9)
2.
02
(1
.8
7,
2.
17
)
£2
2
00
9
1.
24
£1
7
71
8
83
.4
A
ll
A
D
V
A
N
C
E
vs
al
lP
A
R
T
N
E
R
-B
£1
3
15
4
(£
11
20
5,
£1
5
05
5)
0.
78
(0
.7
4,
0.
82
)
£3
4
19
2
(£
30
23
3,
£3
9
36
9)
2.
29
(2
.2
0,
2.
36
)
£2
1
03
8
1.
51
£1
3
94
3
99
.7
*A
ll
va
lu
es
to
be
in
te
rp
re
te
d
as
£
pe
r
Q
A
LY
ga
in
ed
.
†
W
at
t
et
al
9
20
11
,
10
-y
ea
r
tim
e
ho
riz
on
,b
as
e
ca
se
pr
ob
ab
ili
st
ic
re
su
lts
ro
un
de
d
to
ne
ar
es
t
£1
00
.
IC
E
R
,
in
cr
em
en
ta
lc
os
t-
ef
fe
ct
iv
en
es
s
ra
tio
;
M
M
,
m
ed
ic
al
m
an
ag
em
en
t;
Q
A
LY
,
qu
al
ity
-a
dj
us
te
d
lif
e-
ye
ar
s;
TA
V
I,
tr
an
sc
at
he
te
r
ao
rt
ic
va
lv
e
im
pl
an
ta
tio
n.
Brecker S, Mealing S, Padhiar A, et al. Open Heart 2014;1:e000155. doi:10.1136/openhrt-2014-000155 5
Health care delivery, economics and global health care
group.bmj.com on January 6, 2015 - Published by http://openheart.bmj.com/Downloaded from 
The ICERs generated using ﬁxed hospitalisation rates
or ﬁxed utility decrements are below the NICE cost-
effectiveness threshold with the maximum value gener-
ated being £18 577 per QALY gained (table 4, see
online supplementary table S8). Compared to the base
case results in table 2, the impact of using the alternative
modelling approaches was negligible.
The base case analysis assumed that 50% of patients
died in a hospital environment. When the more conser-
vative assumption was made that nobody died in a hos-
pital based environment, the impact on the ICER for
the two main clinical comparisons was an increase in the
ICER of approximately 10% (table 4, see online supple-
mentary table S8). This increase did not result in any of
the ICERs being above the NICE cost-effectiveness
threshold (maximum value £19 481 per QALY gained).
Based on the clinical protocols presented in Orlando
et al,16 we assumed a difference in the cost of treating
an HF hospitalisation event in both arms. When the
TAVI value is used in the MM arm, the impact on the
ICER is an increase of approximately 7% (table 4, see
online supplementary table S8). The ICERs for both
comparisons again remained below the NICE cost-
effectiveness threshold (maximum value £18 883 per
QALY gained).
DISCUSSION
Signiﬁcant advances in medical devices are often
approached with great anticipation and substantial reser-
vations. Following the introduction of TAVI in 2007, its
uptake by the clinical community has been remark-
able,21 yet until the publication of the PARTNER-B study
in 2010 there was no comparative evidence of the clin-
ical and cost-effectiveness of TAVI. Understandably, the
reaction by clinicians and payers has been mixed; while
some have openly welcomed TAVI22 others have voiced
caution and concern at its widespread adoption.23 24
With the publication of the PARTNER-B study and its
encore publications, the clinical and economic case for
TAVI in patients for whom surgical aortic valve replace-
ment (SAVR) is not an option now seems clearer.3 8 25 26
However, the PARTNER-B study was initiated in 2007,
and since then there have been many advances in
device, placement and patient selection, such that the
patient population selected for PARTNER (especially
Figure 3 Cost-effectiveness
plane for all PARTNER-B vs all
ADVANCE and all PARTNER vs
ADVANCE high risk comparisons
with ICERs from five studies;
dashed line represents
willingness to pay of £20 000 per
QALY gained (ICER, incremental
cost-effectiveness ratio; MM,
medical management; QALY,
quality-adjusted life-years; CABG,
coronary artery bypass graft; HF,
heart failure; CRT, cardiac
resynchronization therapy).
Table 3 Sensitivity analysis: exploring alternative MM mortality data sources
MM TAVI Incremental values
Parameter Costs Benefits Costs Benefits Costs Benefits ICER*
PARTNER-B (1 year) £12 972 (£11 080, £15 092) 0.75 (0.70, 0.80) £35 160 (£30 736, £40 248) 2.02 (1.87, 2.17) £22 188 1.27 £17 483
PARTNER-B (2 years) £12 679 (£10 763, £14 669) 0.71 (0.67, 0.75) £35 156 (£30 830, £39 808) 2.02 (1.88, 2.16) £22 478 1.31 £17 165
PARTNER-B (3 years) £13 120 (£11 216, £15 339) 0.78 (0.73, 0.82) £35 129 (£30 790, £39 969) 2.02 (1.87, 2.17) £22 009 1.24 £17 718
PARTNER-B no BAV† £9233 (£7536, £10 938) 0.69 (0.66, 0.73) £35 173 (£30 519, £40 209) 2.02 (1.87, 2.17) £25 940 1.33 £19 500
PARTNER-B with BAV† £13 268 (£11 311, £15 429) 0.69 (0.65, 0.73) £35 214 (£30 820, £40 434) 2.02 (1.87, 2.16) £21 946 1.33 £16 441
PARTNER-B STS <5% £16 148 (£13 846, £18 881) 1.33 (1.27, 1.40) £35 222 (£30 740, £40 378) 2.02 (1.86, 2.17) £19 074 0.69 £27 790
Varadarajan et al £14 734 (£12 607, £17 054) 1.09 (1.02, 1.16) £35 077 (£30 077, £40 329) 2.02 (1.86, 2.17) £20 344 0.93 £21 849
Bouma et al £16 338 (£13 929, £19 119) 1.38 (1.30, 1.45) £35 139 (£30 734, £40 192) 2.02 (1.87, 2.17) £18 751 0.86 £20 667
Data presented as mean, 95% CrI. Time horizon=5 years. TAVI arm based on ADVANCE high-risk group.
*All values to be interpreted as £ per QALY gained.
†Costings altered to reflect alternative assumptions about BAV usage.
BAV, balloon aortic valvuloplasty; CrI, credible interval; ICER, incremental cost-effectiveness ratio; MM, medical management; QALY,
quality-adjusted life-years; TAVI, transcatheter aortic valve implantation.
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Cohort B) no longer represents those treated in clinical
practice. ADVANCE is the ﬁrst study of the Medtronic
CoreValve system and TAVI to have been published since
PARTNER-B. A monitored, independently adjudicated
‘real world’ single arm study, ADVANCE was designed to
evaluate the safety and efﬁcacy of TAVI in 1015 patients
considered inoperable or at high risk for SAVR.
The ADVANCE study provides good-quality data to
explore the efﬁcacy and cost-effectiveness of the
CoreValve system. However, as a single arm study there is
no common comparator with which we could conduct
quantitative evidence synthesis across trials, so we have
used naïve study comparisons to compare treatment
with the CoreValve system alongside MM. Such compari-
sons are limited in their ability to compare across trials,
as there can be many confounding factors, such as dif-
ferences in the baseline characteristics and trial proto-
cols, which may introduce bias to estimates of
comparative effectiveness. One way to accommodate for
this bias is to compare like with like using patient-level
data from all relevant trials.
Without access to the IPD from comparator studies we
have characterised uncertainty in the prognosis of
patients who did not get TAVI by using publicly available
subgroup data from the PARTNER-B cohort to inform a
range of sensitivity analyses. In all of these we have, by
necessity, assumed that the resource use protocols from
the main PARTNER-B cohort, in particular the hospital-
isation rates, are directly applicable to all subgroups.
This is a key limitation of the analyses.
Despite this limitation, using the available data and a
truncated time horizon (5 years), our analysis shows that
TAVI is highly likely to be a cost-effective use of UK
healthcare resources in inoperable patients with AS.
Compared to all patients recruited into PARTNER-B,
individuals in the high-risk ADVANCE cohort (the most
comparable population to the PARTNER-B cohort)
received an increase of 1.24 QALYs at an additional cost
to the healthcare system of £22 009. The ICER was thus
£17 718 per QALY gained and the probability of being
cost-effective at a threshold value of £20 000 per QALY
gained of 83.4%.
Increasing the time horizon that the model is run for
to an approximate patient lifetime (10 years) results in
the ICER falling to £12 003 per QALY gained (100%
cost-effective at the UK decision threshold). Importantly,
the ICERs generated by this analysis are broadly consist-
ent with other published models of TAVI,9 25–30 and
more conservative than the estimates produced by an
independent UK-based Health Technology Assessment
(HTA) of TAVI.16
In reporting the results of this analysis we have consid-
ered and presented ICERs over two distinct time horizons,
5 and 10 years. In the conduct of cost-utility analysis it is
necessary and often required by HTA bodies that ICERs
are presented over the patient’s lifetime; for our purposes
and given the starting age of the population, 10 years was
justiﬁed as being sufﬁcient to meet this requirement.
However, researchers are often sceptical of analyses that
extrapolate overall survival from limited trial follow-up, so
we have also presented our analyses using a 5-year time
horizon. Our current knowledge from the PARTNER-B
cohort informs us that over the 3-year follow-up of the
trial, overall survival in both patient cohorts was predict-
able and readily lends itself to extrapolation. As would be
expected, the time horizon does impact on the ICER,
Figure 4 Deterministic univariate sensitivity analyses (BAV, balloon aortic valvuloplasty; ICU, intensive care unit; MM, medical
management; QALY, quality-adjusted life-years; TAVI, transcatheter aortic valve implantation).
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though in all cases the additional 5 years increases the
QALY gain by less than a third resulting in more favour-
able ICERs under all scenario analyses, which are consist-
ent with the original Watt publication.9
In developing this model we have attempted to
provoke an informed discussion on the likely cost-
effectiveness of TAVI in inoperable patients. To achieve
this we have used the ADVANCE IPD for the CoreValve
system alongside the PARTNER trial and other literature
to generate a large number of scenario analyses, almost
all of which show TAVI to be cost-effective in inoperable
patients. This study gives reassurance that TAVI and the
CoreValve system is likely to be a cost-effective interven-
tion for inoperable patients.
Putting the results of this UK cost-utility analysis into
context, we have included the ICERs of a small number
of other interventions approved by NICE in recent
history in ﬁgure 3. It has been stated in the literature
that TAVI in inoperable patients may only be a palliative
treatment.30 However, TAVI is associated with substantial
improvements in overall survival and QALYs when com-
pared to agents such as sunitinib for renal cancer and
has a better QALY gain than cardiac resynchronisation
therapy vs optimal pharmacological therapy in elderly
patients (>80 years). When considered against the spec-
trum of decisions made by agencies such as NICE, TAVI
represents value for money.
The role of economic evaluations in decision-making is
to inform, not dictate decisions about which healthcare
interventions to fund. In such analyses, researchers
attempt to incorporate all the appropriate evidence into
an analysis to compare the intervention with relevant
alternatives and reﬂect the uncertainty appropriately. In
this analysis the greatest uncertainty is around the treat-
ment effect of TAVI when compared to MM. To represent
our uncertainty we have presented not one survival curve
but a range of possibilities, subgroups and sensitivity ana-
lyses and in the absence of head-to-head comparisons
and comparator IPD this represents the best option avail-
able. Rather than presenting a base case ICER we have
used the results of the sensitivity and subgroup analyses
to demonstrate just how robust the cost-effectiveness
argument for TAVI vs MM is in inoperable patients.
CONCLUSION
With the low mortality and overall improvement in
health-related quality of life found in the ADVANCE
study, TAVI with the CoreValve system has demonstrated
its value in clinical terms. With this analysis we can now
consider the cost-effectiveness of the CoreValve system
against other accepted therapies delivered in the UK
NHS. Despite the high upfront costs of TAVI, it has
proven to deliver substantial improvements in the length
as well as quality of life, and while accommodating for
the uncertainty in our analysis, it is likely to represent a
cost-effective intervention.
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